A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 425-439

  Kamen, Leonard ^a   Henney III, Herbert R ^b   Runyan, Jacob D ^b  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b ACORDA THERAPEUTICS INC   (United States)

Author keywords

Efficacy; Review; Safety; Spasticity; Tizanidine

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMIODARONE; BACLOFEN; CIMETIDINE; CIPROFLOXACIN; CLONAZEPAM; DANTROLENE; DIAZEPAM; DOPAMINE RECEPTOR; ETHINYLESTRADIOL PLUS GESTODENE; FLUVOXAMINE; HYDROCHLOROTHIAZIDE; INTERFERON BETA SERINE; METHYLPHENIDATE; MEXILETINE; NITROFURANTOIN; NORFLOXACIN; OPIATE RECEPTOR; ORAL CONTRACEPTIVE AGENT; OXYBUTYNIN; PARACETAMOL; PHENYTOIN; PLACEBO; PROPAFENONE; ROFECOXIB; TICLOPIDINE; TIZANIDINE;

ADD ON THERAPY; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASTHENIA; ATAXIA; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CHOLESTASIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FIRST PASS EFFECT; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPOTENSION; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; MEDLINE; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NONHUMAN; PRESYNAPTIC NERVE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SPASTICITY; SPINAL CORD; SPINAL CORD INJURY; STROKE; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEAKNESS; WITHDRAWAL SEIZURE; XEROSTOMIA;

BRAIN INJURIES; CLONIDINE; DISEASE PROGRESSION; DRUG INTERACTIONS; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE RELAXANTS, CENTRAL; SPASM; SPINAL CORD INJURIES; STROKE;

EID: 39749201642     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X261113     Document Type: Review

References (92)

1. WE MOVE: Spasticity - Overview. Available at http://www.wemove.org/spa/ spa_overview.html [accessed 10 September 2007]
2. Young RR. Spasticity: a review. Neurology 1994;44:S12-20
3. Adams MM, Hicks AL. Spasticity and spinal cord injury. Spinal Cord 2005;43,577-86
4. Rizzo MA, Hadjimichael OC, Preiningerva J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10:589-95
5. WE MOVE™: Spasticity. Available at http://www.mdvu.org/library/ disease/spasticity/ [accessed 2 May 2007]
6. Inman RP. The economic consequences of a debilitating illness: the case of multiple sclerosis. Rev Econ Stat 1987;69: 651-60
7. Bourdette DN, Prochazka AV, Mitchell W, et al. VA Multiple Sclerosis Study Group. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. Arch Phys Med Rehabil 1993;74:26-31
8. Catanzaro M, Weinert C. Economic status of families living with multiple sclerosis. Int J Rehabil Res 1992;15:209-18
9. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998:4;419-25
10. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross sectional study in the United States. Neurology 2006:66;1696-702
11. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
12. Haselkorn JK, Balsdon Richer C, Fry Welch D, et al. Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis. J Spinal Cord Med 2005;28:167-99
13. Nance PW, Shears AH, Nance DM. Clonidine in spinal cord injury. Can Med Assoc J 1985;133:41-2
14. Nance PW, Shears AH, Nance DM. Reflex changes induced by clonidine in spinal cord injured patients. Paraplegia 1989;27:296-301
15. Dall JT, Harmon RL, Quinn CM. Use of clonidine for treatment of spasticity arising from various forms of brain injury: a case series. Brain Inj 1996;10:453-8
16. Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology 1994;44:S6-11
17. Donovan WH, Carter RE, Rossi CD, Wilkerson MA. Clonidine effect on spasticity: a clinical trial. Arch Phys Med Rehabil 1988;69:193-4
18. Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmac ology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435-52
19. Sayers AC, Burki HR, Eichenberger E. The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS103-282), a novel myotonolytic agent. Arzneimittelforschung 1980;30:793-803
20. Mathias CJ, Luckitt J, Desai P, et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev 1989;26:9-16
21. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103-282). Br J Pharmacol 1982;76:473-81
22. Curtis DR, Leah JD, Peet MJ. Spinal interneurone depression by DS103-282. Br J Pharmacol 1983;79:9-11
23. Newman PM, Nogues M, Newman PK, et al. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol 1982;23:31-5
24. Tanabe M, Kaneko T, Tonohiro T, Iwata N. The pharmacological properties of CS-722, a newly synthesized centrally acting muscle relaxant. Neuropharmacology 1992;31:1059-66
25. Emre M, Leslie GC, Muir C, et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud®). J Neurol Neurosurg Psychiatry 1994;57:1355-9
26. Knutsson E, Martensson A, Gransberg L. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. J Neurol Sci 1982;53:187-204
27. Hassan N, McLellan DL. Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. J Neurol Neurosurg Psychiatry 1980;43:1132-6
28. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994;44:S60-8
29. Nomura M, Kusaba-Suzuki M, Kimura T, et al. Cardiovascular effects of tizanidine, a new centrally acting muscle relaxant, in rats and dogs. Pharmacometrics 1985;29:477-91
30. Skoog B. A comparison of the effects of two antispastic drugs, tizanidine and baclofen, on synaptic transmission from muscle spindle afferents to spinal interneurones in cats. Acta Physiol Scand 1996;156:81-90
31. Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997;54:731-6
32. Taittonen M, Raty H, Kirvela O, et al. The metabolic effects of oral tizanidine in healthy volunteers. Acta Anaesthesiol Scand 1995;39:628-32
33. Davies J, Johnston SE. Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord. Br J Pharmacol 1984;82:409-21
34. Kameyama T, Nabeshima T, Matsuno K, Sugimoto A. Comparison of alpha-adrenoceptor involvement in the antinociceptive action of tizanidine and clonidine in the mouse. Eur J Pharmacol 1986;125:257-64
35. Kameyama T, Nabeshima T, Sugimoto A, et al. Antinociceptive action of tizanidine in mice and rats. Naunyn Schmiedebergs Arch Pharmacol 1985;330:93-6
36. Ali BH, Bashir AA. The effect of some alpha 2-adrenoceptor agonists and antagonists on gastrointestinal transit in mice: influence of morphine, castor oil and glucose. Clin Exp Pharmacol Physiol 1993;20:1-6
37. Ramabadran K, Bansinath M, Turndorf H, Puig MM. Streptozotocin-diabetes attenuates alpha 2-adrenoceptor agonist-induced delay in small intestinal transit in mice. J Auton Pharmacol 1990;10:163-71
38. Maeda-Hagiwara M, Watanabe H, Kanaoka R, Watanabe K. Reduction of centrally-stimulated gastric acid secretion by tizanidine, a new imidazoline derivative, in anesthetized rats. Arch Int Pharmacodyn Ther 1985;277:321-7
39. Heazlewood V, Symoniw P, Maruff P, Eadie MJ. Tizanidine - initial pharmacokinetic studies in patients with spasticity. Eur J Clin Pharmacol 1983;25:65-7
40. Koch P, Hirst DR, von Wartburg BR. Biological fate of Sirdalud in animals and man. Xenobiotica 1989;19:1255-65
41. Shellenberger MK, Groves L, Shah J, Novack GD. A controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state. Drug Metab Dispos 1999;27:201-4
42. Tse FL, Jaffe JM, Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundam Clin Pharmacol 1987;1:479-88
43. Henney 3rd HR, Shah J. Relative bioavailability of tizanidine tablet and capsule formulations after a standard high-fat meal: a single-dose, open-label, randomized, crossover study in healthy subjects. Clin Ther 2007;29:661-9
44. Roberts RC, Part NJ, Pokorny R, et al. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology 1994;44:S29-31
45. Zanaflex Capsules™ and Zanaflex® tablets [package insert]. Hawthorne, NY: Acorda Therapeutics; 2006
46. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998;15:241-51
47. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 2004;57:349-53
48. Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005;78:400-11
49. Granfors MT, Backman JT, Neuvonen M, et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 2004;75:331-41
50. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004;76:598-606
51. Backman JT, Karjalainen MJ, Neuvonen M, et al. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 2006;62:345-57
52. Ueno K, Miyai K, Mitsuzane K. Phenytoin-tizanidine interaction. Ann Pharmacother 1991;25:1273
53. Guidance for Industry. Statistical Approaches to Establishing Bioequivalence. Washington, DC: US Food and Drug Administration, Center for Drug Evaluation and Research; 2001
54. Shah J, Wesnes KA, Kovelesky RA, Henney HR, 3rd. Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clin Ther 2006;28:1308-17
55. Wesnes KA, Meulenberg O, Vermeij B, et al. The acute cognitive effects of amitriptyline, hydroxyzine and lorazepam in volunteers. J Psychopharmacol 1996;10(Suppl):A51
56. Wesnes KA, Walker MB, Walker LG, et al. Cognitive performance and mood after a weekend on call in a surgical unit. Br J Surg 1997;84:493-5
57. Wesnes KA, Garratt C, Wickens M, et al. Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. Br J Clin Pharmacol 2000;49:110-17
58. Wesnes KA, Ward T, McGinty A, Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl) 2000;152:353-61
59. Wesnes KA, McKeith IG, Ferrara R, et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 2002;13:183-92
60. Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl) 2000;151:416-23
61. Kennedy DO, Scholey AB, Wesnes KA. Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutr Neurosci 2001;4: 399-412
62. Kennedy DO, Scholey AB, Wesnes KA. Dose dependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers. Nutr Neurosci 2001;4:295-310
63. Nance PW, Bugaresti J, Shellenberger K, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology 1994;44:S44-51
64. Ash worth B. Preliminary trial of carisoprodal in multiple sclerosis. Practitioner 1964;192:540-2
65. Wartenburg R. Pendulousness of the legs as a diagnostic test. Neurology 1951;1:18-24
66. Coward DM, Davies J, Herding P, Rudeberg C. Pharmacological Properties of Tizanidine (DS103-282). New York, NY: Springer-Verlag NY Inc.; 1984:61-71
67. Emre M. Review of clinical trials with Sirdalud in spasticity. In: Emre M, Benecke R, eds. Spasticity. Pearl River, NY: Parthenon Publishing, 1989
68. Nance PW. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc 1994;17:151-7
69. Smith C, Birnbaum G, Carter JL, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994;44:S34-42
70. The United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994;44:S70-8
71. Gelber DA, Good DC, Dromerick A, et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke 2001;32:1841-6
72. Meythaler JM, Guin-Renfroe S, Johnson A, et al. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil 2001;82:1155-63
73. Kita M, Goodkin DE. Drugs used to treat spasticity. Drug 2000;59:487-95
74. Gracies JM, Nance P, Elovic E, et al. Traditional pharmacological treatments for spasticity part II: General and regional treatments. Muscle Nerve 1997;(Suppl 6) S92-120
75. Anonymous: Central Nervous System Agents. In: Kastrup E, Wickersham R, Novak K, et al., eds. Drug Facts and Comparisons. St. Louis, MO: Wolters Kluwer Health, 2007:1021-582
76. Eyssette M, Rohmer F, Serratrice G, et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988;10:699-708
77. Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988;15:15-19
78. Medici M, Pebet M, Ciblis D. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Curr Med Res Opin 1989;11:398-407
79. Stien R, Nordal HJ, Oftedal SI, Slettebo M. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987;75:190-4
80. Hoogstraten MC, van der Ploeg RJ, vd Burg W, et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand 1988;77:224-30
81. Pagano M, Ferreiro M, Herskovis E. Comparative study of tizanidine and baclofen in patients with chronic spasticity. Rev Neurol Argent 1988;14:268-76
82. Rinne U. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res 1980;28: 827-36
83. Smolenski C, Muff S, Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981;7:374-83
84. Bes A, Eyssette M, Pierrot-Deseilligny E, et al. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin 1988;10:709-18
85. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004;28:140-75
86. Ferrendelli, JA. Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy. Neurology 1995;45(3 Suppl 2):S12-16
87. Kinsbury SJ, Yi D, Simpson GM. Rational and irrational polypharmacy. Psychiatr Serv 2001;52:1033-6
88. Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 1994;44:S53-9
89. Rustemovic N, Huic M, Opacic M. Tizanidine-induced acute toxic hepatitis: case report. Pharmaca 1994;32:457-61
90. de Graaf EM, Oosterveld M, Tjabbes T, Stricker BH. A case of tizanidine-induced hepatic injury. J Hepatol 1996;25: 772-3
91. Spiller HA, Bosse GM, Adamson LA. Retrospective review of tizanidine (Zanaflex®) overdose. J Toxicol 2004;42:593-6
92. Data on file. Acorda Therapeutics, Inc. Clinical Trial Report for Study AN021-101. September 2001